
Cell & Gene Therapy Manufacturing Services Market Insights, Size and Growth Forecast To 2030
Cell & Gene Therapy Manufacturing Services Market Size, Share & Trends Analysis By Type, By Indication, By Application, By End-user, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Published: Jun-2022 | Report ID: BIOT2229 | Pages: 1 - 245 | Formats*: |
Category : Biotechnology |
Report Metric | Details |
Market size available for years | 2019-2030 |
Base year considered | 2021 |
Forecast period | 2022-2030 |
Segments covered | By Product, By Region |
Geographies covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
Companies Covered | ABL Inc., Andelyn Biosciences, Anemocyte Srl, BioCentriq, Catalent, Inc., Cell and Gene Therapy Catapult, Charles River Laboratories, Commercializing Living Therapies, ElevateBio, F. Hoffmann-La Roche Ltd., FinVector, FUJIFILM Holdings Corporation, JRS PHARMA, Lonza, Merck KGaA, NIKON CORPORATION, Oxford Biomedica plc, Porton Biopharma Limited, Resilience, RoslinCT, Takara Bio Inc., The Discovery Labs LLC, Thermo Fisher Scientific, Inc., Vibalogics, WuXi AppTec |
1.1. Scope of the report1.2. Market segment analysis
2.1 Research data source
2.1.1 Secondary data2.1.2 Primary data2.1.3 SPER’s internal database2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers4.1.2 Restraints4.1.3 Opportunities4.1.4 Challenges
4.2. COVID-19 Impacts of the Cell & Gene Therapy Manufacturing Services Market
5.1. SWOT analysis
5.1.1 Strengths5.1.2 Weaknesses5.1.3 Opportunities5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape5.2.2 Economic landscape5.2.3 Social landscape5.2.4 Technological landscape5.2.5 Environmental landscape5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers5.3.2 Bargaining power of Buyers5.3.3 Threat of Substitute5.3.4 Threat of new entrant5.3.5 Competitive rivalry
5.4. Heat map analysis
6.1. Cell Therapy
6.1.1. Allogeneic6.1.1.1. Hematopoietic Stem Cells6.1.1.2. Induced Pluripotent Stem Cells6.1.1.3. Mesenchymal Stem Cells6.1.1.4. Natural Killer Cells6.1.1.5. Other Allogeneic Cells6.1.1.6. T-cells6.1.2. Autologous6.1.2.1. Hematopoietic Stem Cells6.1.2.2. Mesenchymal Stem Cells6.1.2.3. Natural Killer Cells6.1.2.4. T-cells6.1.3. Viral Vector6.1.3.1. Adeno-associated Virus Vectors6.1.3.2. Other Viral Vectors6.1.3.3. Retroviral Vectors
6.2. Gene Therapy
6.2.1. Non-viral Vector6.2.2. Oligonucleotides6.2.2.1. Other Non-viral Vectors6.2.3. Viral Vector6.2.3.1. Retroviral Vectors6.2.3.2. Adeno-associated Virus Vectors6.2.3.3. Other Viral Vectors
7.1. Cardiovascular Diseases7.2. Central Nervous System Disorders7.3. Infectious Diseases7.4. Oncology Diseases7.5. Ophthalmology Diseases7.6. Orthopedic Diseases7.7. Other Indications
8.1. Clinical Manufacturing8.2. Commercial Manufacturing
9.1. Academic & Research Institutes9.2. Other End Users9.3. Pharmaceutical & Biotechnology Companies
10.1. North America
10.1.1. United States10.1.2. Canada10.1.3. Mexico
10.2. Europe
10.2.1. Germany10.2.2. United Kingdom10.2.3. France10.2.4. Italy10.2.5. Spain10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China10.3.2. Japan10.3.3. India10.3.4. Australia10.3.5. South Korea10.3.6. Rest of Asia-Pacific
10.4. South America
10.4.1. Brazil10.4.2. Argentina10.4.3. Rest of South America
10.5. Middle East & Africa
10.5.1. Kingdom of Saudi Arabia10.5.2. United Arab Emirates10.5.3. Rest of Middle East & Africa
11.1. ABL, Inc.
11.1.1. Company details11.1.2. Financial outlook11.1.3. Product summary11.1.4. Recent developments
11.2. Andelyn Biosciences
11.2.1. Company details11.2.2. Financial outlook11.2.3. Product summary11.2.4. Recent developments
11.3. Anemocyte Srl
11.3.1. Company details11.3.2. Financial outlook11.3.3. Product summary11.3.4. Recent developments
11.4. BioCentriq
11.4.1. Company details11.4.2. Financial outlook11.4.3. Product summary11.4.4. Recent developments
11.5. Catalent, Inc.
11.5.1. Company details11.5.2. Financial outlook11.5.3. Product summary11.5.4. Recent developments
11.6. Cell and Gene Therapy Catapult
11.6.1. Company details11.6.2. Financial outlook11.6.3. Product summary11.6.4. Recent developments
11.7. Charles River Laboratories
11.7.1. Company details11.7.2. Financial outlook11.7.3. Product summary11.7.4. Recent developments
11.8. Commercializing Living Therapies
11.8.1. Company details11.8.2. Financial outlook11.8.3. Product summary11.8.4. Recent developments
11.9. ElevateBio
11.9.1. Company details11.9.2. Financial outlook11.9.3. Product summary11.9.4. Recent developments
11.10. F. Hoffmann-La Roche Ltd.
11.10.1. Company details11.10.2. Financial outlook11.10.3. Product summary11.10.4. Recent developments
11.11. FinVector
11.11.1. Company details11.11.2. Financial outlook11.11.3. Product summary11.11.4. Recent developments
11.12. FUJIFILM Holdings Corporation
11.12.1. Company details11.12.2. Financial outlook11.12.3. Product summary11.12.4. Recent developments
11.13. JRS PHARMA
11.13.1. Company details11.13.2. Financial outlook11.13.3. Product summary11.13.4. Recent developments
11.14. Lonza
11.14.1. Company details11.14.2. Financial outlook11.14.3. Product summary11.14.4. Recent developments
11.15. Merck KGaA
11.15.1. Company details11.15.2. Financial outlook11.15.3. Product summary11.15.4. Recent developments
11.16. NIKON CORPORATION
11.16.1. Company details11.16.2. Financial outlook11.16.3. Product summary11.16.4. Recent developments
11.17. Oxford Biomedica plc
11.17.1 Company details11.17.2 Financial outlook11.17.3 Product summary11.17.4 Recent developments
11.18. Porton Biopharma Limited
11.18.1. Company details11.18.2. Financial outlook11.18.3. Product summary11.18.4. Recent developments
11.19. Resilience
11.19.1. Company details11.19.2. Financial outlook11.19.3. Product summary11.19.4. Recent developments
11.20. RoslinCT
11.20.1. Company details11.20.2. Financial outlook11.20.3. Product summary11.20.4. Recent developments
11.21. Takara Bio Inc.
11.21.1. Company details11.21.2. Financial outlook11.21.3. Product summary11.21.4. Recent developments
11.22. The Discovery Labs LLC
11.22.1. Company details11.22.2. Financial outlook11.22.3. Product summary11.22.4. Recent developments
11.23. Thermo Fisher Scientific, Inc.
11.23.1. Company details11.23.2. Financial outlook11.23.3. Product summary11.23.4. Recent developments
11.24. Vibalogics
11.24.1. Company details11.24.2. Financial outlook11.24.3. Product summary11.24.4. Recent developments
11.25. WuXi AppTec
11.25.1 Company details11.25.2 Financial outlook11.25.3 Product summary11.25.4 Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment






Related Reports
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.